Amarin Corporation plc (ADR) (NASDAQ:AMRN) has announced that it would be holding its conference call for the 3Q2016, on November 3. The company would discuss its finances for the quarter and also provide an operational update to investors. The call is scheduled for 730 am, ET and would follow the filing of the quarterly results, earlier in the day.
The company has stated that participants of the call would be allowed to ask questions, subject to time limitations. Alternatively, investors can email their questions to AMRN’s investor relations, by 4 pm, ET, November 2, 2016. The call can be listened to by phone or through a webcast on the investor relations section of the company’s website. A replay of the call would be available for the next two weeks.
Earlier, the company released a smaller sized Vascepa capsule, 0.5 gram, which is now available in retail pharmacies. Aaron Berg, the senior VP of marketing and sales at AMRN, claimed that this was done after listening to feedback from customers and health professionals. He further clarified that the patients had difficulty in taking the 1 gram capsules, which created the need for a smaller alternative. It should be noted here that the FDA approved dosage for Vascepa is 4 grams per day, to be taken 2 grams twice daily. As such, the company believes that most patients would still be prescribed the original 1 gram capsules.
In addition to this, Amarin continues to make progress with its REDUCE-IT study of the drug. The company recently announced that an independent data monitoring committee had completed its interim review of the study. The committee determined that the trial should continue, without any modifications. The study is aimed at determining if cardiovascular events are reduced, when treated with Vascepa and has a patient population of 8,175.
Amarin Corporation plc (ADR) (NASDAQ:AMRN) recorded a trade volume of 6.96 million and lost 5.28% of its share value, during the October 28 trading session, to close at $3.23 per share.
